Why the study?
To address the balance of benefit and risk regarding gastrointestinal bleeding in patients with ischemic heart disease receiving antithrombotic therapy.
How can the risk of upper gastrointestinal bleeding be managed in patients with ischemic heart disease receiving antithrombotic therapy?
How can the risk of upper gastrointestinal bleeding be managed in patients with ischemic heart disease receiving antithrombotic therapy?
This review outlines strategies for risk stratification and prevention of upper gastrointestinal bleeding in patients with ischemic heart disease on antithrombotic therapy.
Answers are grounded in this paper and cite their sources.
May guide GI bleeding prevention in IHD on antithrombotics; leaves open prospective validation of recommendations.
The review focuses on upper gastrointestinal (GI) bleeding in patients with ischemic heart disease (IHD) receiving an antithrombotic therapy. Approaches to risk stratification for GI bleeding and correction of modifiable factors that determine the probability of such events are addressed in detail. Recommendations are provided for administration of stomach-protecting drugs. The interrelation of risk factors for thromboses and bleedings is stressed, and possible indications for a multicomponent antithrombotic therapy in patients with stable IHD are discussed.
No takes yet. Share an insight, caveat, or question.
Комаров et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: